Lilly adds to immune drug pipeline with $2.9B Merida buyout
admin Eli Lilly and Company, a global pharmaceutical giant, announced on August 31, 2026, its strategic...
Biotech, Pharma & Cancer Drug Development
Major Cell Therapy Developers Novartis and Bristol Myers Squibb Halt Autoimmune Disease Trials Amid Inflammatory Side Effects
The burgeoning field of cell therapy for autoimmune diseases has hit a significant roadblock, as...
Takeda’s Mimrylo Secures FDA Clearance with Broad Label, Poised for Multi-Billion Dollar Annual Revenue Opportunity
The U.S. Food and Drug Administration (FDA) has granted clearance for Mimrylo, Takeda Pharmaceutical Company’s...
Verily, NVIDIA, and NIH Pioneer Multimodal AI Integrating EHR and Genomic Data for Enhanced Disease Prediction
The frontier of artificial intelligence in healthcare has taken a significant leap forward with the...
FDA Approves Lisraya (Brepocitinib) as First Oral Therapy for Rare Dermatomyositis, Marking a Milestone for Priovant Therapeutics
The U.S. Food and Drug Administration (FDA) has granted approval for brepocitinib, marketed as Lisraya,...
Biotech Sector Surges to Historic Peaks in August 2026, Fueled by Record IPOs and Robust M&A Activity Amidst Strategic Pipeline Refill Initiatives
The biotechnology sector is experiencing an unprecedented resurgence in August 2026, marked by the benchmark...
AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease
Two years ago, Alnylam Pharmaceuticals unveiled groundbreaking study data, demonstrating that patients suffering from a...
Biopharma Dive’s Week in Review: FDA Vaccine Updates, Moderna’s Financial Gambit, Data Leak Fallout, and Critical Therapeutic Advancements
The biopharmaceutical sector witnessed a flurry of significant developments this past week, marked by crucial...
Revolutionary Pancreatic Cancer Drug Rasonque Launched with $39,800 Monthly Price, Exceeding Expectations and Igniting Hope for Patients
The pharmaceutical landscape for metastatic pancreatic cancer has been fundamentally reshaped with the immediate launch...
Tezspire’s Success in Eosinophilic Esophagitis Trial Paves Way for Third Indication and Blockbuster Market Expansion
AstraZeneca and Amgen have announced a significant clinical triumph for their co-developed biologic, Tezspire (tezepelumab),...
